Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.44 USD | +1.87% | +3.92% | -12.96% |
01/04 | Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating | MT |
01/04 | HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.96% | 8.28Cr | |
+8.29% | 11TCr | |
+10.21% | 10TCr | |
+0.73% | 2.23TCr | |
-11.90% | 2.24TCr | |
-5.52% | 1.91TCr | |
-37.36% | 1.8TCr | |
-5.17% | 1.79TCr | |
+7.70% | 1.43TCr | |
+37.65% | 1.25TCr |
- Stock Market
- Equities
- AFMD Stock
- News Affimed N.V.
- Affimed N.V.'s Potential Therapy for Lymphoma Shows 100% Objective Response Rate in Phase 1/2 Study